Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Researchers Use Physics Technology to Develop Rapid Antigen COVID-19 Test

By LabMedica International staff writers
Posted on 10 Nov 2020
Researchers have adapted technology that is typically used for physics applications to create a rapid antigen COVID test that has been able to detect viral proteins in minutes with high accuracy.

Currently, PCR-, antigen-, and antibody-based technologies have been at the forefront in the development of COVID testing. More...
However, scientists are looking into other technologies not usually used in the life sciences in order to improve the detection of the virus. Researchers from the Department of Materials Science and Engineering at the Massachusetts Institute of Technology (Cambridge, MA, USA) have developed a test called TriboSense One that does not have an optical readout for detecting viruses like many current tests on the market, but instead provides a mechanical readout to assess the strength of biomolecular interactions, looking at friction to detect a sample's molecular interactions and confirm the presence of the virus in very small concentrations.

The instrument measures how molecules in saliva affect the motion of sensing beads with magnetic properties to determine whether SARS-CoV-2 viruses are present or not. The beads and the saliva are mixed together during sample prep. Currently, the test detects the spike protein of the virus, but the magnetic sensing particles can also be customized to stick to different types of proteins, for example the nucleocapsid protein of SARS-CoV-2, which the researchers are also pursuing. Once the saliva sample is collected, the consumer's job is quite simple, consisting mostly of pipetting the sample into the solution. The technology was originally created to measure protein-protein, protein-DNA, DNA-DNA and other biomolecular interactions. Eventually, the team wants to expand testing to other diseases, but the focus now is on COVID-19. The testing system could potentially benefit point-of-care settings because of its small size and portability. The test is also inexpensive; while it costs around USD 5-6 right now, at scale it could even cost as little as USD 3.

"We had to go from scratch," said MIT Professor Alfredo Alexander-Katz. "We had never worked on viruses … and we adapted the technology to be able to do this."

Related Links:
Massachusetts Institute of Technology


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.